Rnai reagent and composition for inhibiting expression of transthyretin (TTR), and use
Patent Information
- Application Number
- HK62026125182
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-06
- Filing Date
- 2026-06-23
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202480068670.9 (22) Application Date 2024.10.18 (66) Domestic Priority Data 202311470890.8 2023.11.06 CN (85) PCT International Application Entering National Phase Date 2026.04.24 (86) PCT International Application Application Data PCT / CN2024 / 125847 2024.10.18 (87) PCT International Application Publication Data WO2025 / 098117 ZH 2025.05.15 (71) Applicant Chengdu Betterma Biomedical Technology Co., Ltd. Address 610094 No. 1, 1st Floor, Building 3, No. 263, Hexiang Third Street, High-tech Zone, Chengdu, Sichuan Province Applicant: Chengdu Better Pharmaceutical Co., Ltd. (72) Inventors: Luo Feng, Zang Chao, Huang Guobing, Yu Shuowen Permit: Huang Haoxi, Su Zhonghai (74) Patent Agency: Beijing Xinno Chuangcheng Intellectual Property Agency Co., Ltd. 11728 Patent Attorney: Hao Wenting, Chen Yuejun (51) Int.Cl. C12N 15 / 113 (2006.01) A61K 31 / 713 (2006.01) A61K 47 / 61 (2006.01) (54) Invention Title: An RNAi reagent, composition and application for inhibiting the expression of thyroxine transporter (TTR) (57) Abstract: An RNAi reagent and composition for inhibiting the expression of thyroxine transporter (TTR) can be used to treat and / or prevent ATTR Related diseases include ATTR-PN (thyroxine transporter amyloid polyneuropathy), ATTR-CM (thyroxine transporter amyloid cardiomyopathy), senile systemic amyloidosis, and meningeal / central nervous system amyloidosis. CN 122122299 A 2026.05.29 CN 1 22 12 22 99 A
